Navigation Links
Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies with REOLYSIN(R)
Date:7/14/2008

- Company to Host Conference Call to Update Clinical Program -

CALGARY, July 14 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has now enrolled and treated 200 cancer patients in clinical studies with REOLYSIN(R), its proprietary formulation of the human reovirus.

"The clinical program has gained substantial momentum in the past year, culminating in the treatment of our 200th patient this week," said Dr. Brad Thompson, President and CEO of Oncolytics. "REOLYSIN(R) has been well tolerated by the patients, and has demonstrated activity in all trials reported on to date. Our current studies will allow us to design our pivotal program based on Phase II data from human clinical studies."

Together with its collaborators, Oncolytics is now recruiting or enrolling patients in ten Phase I/II or Phase II clinical trials with REOLYSIN(R) in the U.S. and the U.K., and has permission to begin another Phase II trial in the U.S. These trials include four monotherapy trials using REOLYSIN(R) alone, and seven trials using REOLYSIN(R) in combination with radiation or chemotherapy.

Conference Call Details

Dr. Brad Thompson, President and CEO of Oncolytics, will host a conference call on Wednesday, July 16, 2008 at 11:30 a.m. MST (1:30 p.m. EST) to update investors on the Company's current and future clinical program for REOLYSIN(R).

To access the conference call by telephone, dial 1-416-644-3414 or 1-800-733-7571. A live audio webcast will be available through the Company's website at http://www.oncolyticsbiotech.com. Please connect at least 15 minutes prior to the webcast to ensure adequate time for any software download that may be needed. A replay of the webcast will be available at http://www.oncolyticsbiotech.com and will also be available by teleph
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
2. Oncolytics Biotech Inc. to Present at BIO 2008 International Convention
3. Oncolytics Biotech Inc. Announces Start of Enrolment in Phase 1/2 Ovarian Cancer Clinical Trial with REOLYSIN(R)
4. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
5. Oncolytics Biotech Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
6. Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at ASGT Meeting
7. Oncolytics Biotech Inc. Announces Issuance of 9th Canadian Patent
8. Oncolytics Biotech Inc. Transfers 40-Litre cGMP Manufacturing Process for REOLYSIN(R)
9. Oncolytics Biotech Inc. Announces Issuance of 27th U.S. Patent
10. Oncolytics Biotech Inc. Collaborators to Present Phase II Sarcoma Trial Results at ASCO Annual Meeting
11. Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Massachusetts , September 2, 2014 ... to BioData,s research and lab management services  ... management service, is pleased to announce the appointment of ... Culot most recently served as VP Marketing and Business ... life science research and clinical applications. Previously, ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 The ... and Diagnostics report provides comprehensive understanding and unprecedented ... entered into by the worlds leading life science ... and analysis of how and why companies enter ... a prospective partner’s negotiated deals terms provides critical ...
(Date:8/31/2014)... 2014 This is a professional ... the Epoxy Hardener industry in Global and ... the industry, including definitions, applications and industry chain ... analysis are provided with a focus on history, ... A comparison between the international and Chinese situation ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 The ... $5.6 billion in 2019. It is expected to ... to 2019, and was valued at $1.8 billion ... by Transparency Market Research. , For more information ... http://www.transparencymarketresearch.com/companion-diagnostics-market.html . , The research report, titled “Companion ...
Breaking Biology Technology:Louis Culot Appointed as BioData's CEO 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 4Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 2Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 3Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3
... Idenix Pharmaceuticals, Inc., (NASDAQ: IDIX ) announced today ... quarter of 2011 on Monday, August 8, 2011 after U.S. ... conference call at 4:30 p.m. ET on Monday, August 8, ... quarter of 2011 and provide an update on the company,s ...
... LOS ANGELES, July 21, 2011 Genesis Biopharma, Inc. ... today announced it has named retired four-star General Merrill ... served nearly four decades in the U.S. Air Force ... 1994.  The Genesis Biopharma Board now consists of 7 ...
... 2011 Sangamo BioSciences, Inc. (Nasdaq: ... use of zinc finger nucleases (ZFNs) to produce genetically modified ... of the National Academy of Sciences (PNAS) , represents a ... tissue as a source for transplant into humans.   ...
Cached Biology Technology:Genesis Biopharma Names Former Member of the Joint Chiefs of Staff General Merrill McPeak to Board of Directors 2Sangamo BioSciences Announces Efficient Generation of Transgenic Pigs Using Zinc Finger Nuclease (ZFN) Technology 2Sangamo BioSciences Announces Efficient Generation of Transgenic Pigs Using Zinc Finger Nuclease (ZFN) Technology 3Sangamo BioSciences Announces Efficient Generation of Transgenic Pigs Using Zinc Finger Nuclease (ZFN) Technology 4
(Date:8/31/2014)... A new blood test provides a fast and ... new proof-of-concept study shows. The newly developed test ... to detect active tuberculosis in children. The test ... tests in combination with speed of a blood ... for the diagnosis of tuberculosis in children, particularly ...
(Date:8/31/2014)... not busy attacking us, germs go after each other. ... disaster for the infected microbes: Sometimes viruses actually carry ... expand its diet or better attack its own hosts. ... immune system would robotically destroy anything it recognized as ... have now revealed that one variety of the bacterial ...
(Date:8/31/2014)... Over the past several decades, malaria diagnosis has changed very ... technician smears the blood across a glass slide, stains it ... the Plasmodium parasite, which causes the disease. This approach gives ... blood an important measure of disease severity but ... , A research team from the Singapore-MIT Alliance for Research ...
Breaking Biology News(10 mins):New tuberculosis blood test in children is reliable and highly specific 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 3A new way to diagnose malaria 2A new way to diagnose malaria 3
... such, they are relatively well studied, especially in the ... most thoroughly. First eastern US butterfly species were described ... himself, over 250 years ago. For the last ... species diversity of eastern butterflies, and every nook and ...
... A*STAR,s Institute of Molecular and Cell Biology (IMCB) have ... the pathway leading to memory and learning impairment. The ... and could be used to explain defects in the ... established knowledge could potentially facilitate exploration of strategies to ...
... plant that,s been known to drive people daffy. It,s one ... a hard-to-control weed in ponds and small lakes. But it,s ... source to produce pharmaceuticals. Now, the genome of Greater Duckweed ... as a biofuel source a big boost. In a paper ...
Cached Biology News:Two new butterfly species discovered in eastern USA 2A*STAR scientists discover protein's role in human memory and learning functions 2Pond-dwelling powerhouse's genome points to its biofuel potential 2Pond-dwelling powerhouse's genome points to its biofuel potential 3Pond-dwelling powerhouse's genome points to its biofuel potential 4
... CE 4100 high pressure pump with ... with software drive compensation, reducing pulsing to ... selectable in 0.001mL steps. , The pump ... bio-compatible., Pumps may be programmed from their ...
... filter paper sandwiches are composed of a ... of thick filter paper that are preassembled ... sandwich. These 7 x 8.5 cm membrane ... Ready Gel-sized gels and are supplied as ...
... assay kit I provides reagents and a protein ... of reducing agents and detergents. The RC DC ... includes reagents and standards sufficient for 500 standard ... RC reagent II, 250 ml alkaline copper tartrate ...
... is a state-of-the-art separation system using the ... The Eclipse integrates easily with Wyatts multi-angle ... as well as the Optilab DSP. The ... mass distributions of the particles/molecules separated by ...
Biology Products: